» Articles » PMID: 18226517

Ethical and Human Rights Imperatives to Ensure Medication-assisted Treatment for Opioid Dependence in Prisons and Pre-trial Detention

Overview
Publisher Elsevier
Date 2008 Jan 30
PMID 18226517
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Opioid dependence is a complex medical condition affecting neurocognitive and physical functioning. Forced or abrupt opioid withdrawal may cause profound physical and psychological suffering, including nausea, vomiting, diarrhoea, extreme agitation and/or anxiety. Opioid-dependent individuals are especially vulnerable at the time of arrest or initial detention, when they may, as a result of their chemical dependency, be coerced into providing incriminating testimony, or be driven to engage in risky behaviour (such as sharing needles in detention) in order to avoid painful withdrawal symptoms. Upon incarceration, many opioid-dependent prisoners are forced to undergo abrupt opioid withdrawal (both from legally prescribed agonist therapy such as methadone as well as illicit opioids). Physical and psychological symptoms attendant to withdrawal may impair capacity to make informed legal decisions, and cause prisoners to risk HIV and other blood-borne diseases by sharing injection equipment. Although prisons must provide at least the standard of care to prisoners that is available in the general population, medication-assisted treatment, endorsed by international health and drug agencies as an integral part of HIV prevention and care strategies for opioid-dependent drug users, is unavailable to most prisoners. Medication-assisted treatment is a well-studied and validated pharmacological therapy for the medical condition known as opioid dependence. The failure to ensure prisoner access to this medical therapy threatens fundamental human rights protections against cruel, inhuman or degrading treatment and rights to health and to life. It also poses serious ethical problems for health care providers, violating basic principles of beneficence and non-maleficence (i.e., do good/do no harm). Governments must take immediate action to ensure access to opioid substitution to prisoners to ensure fulfilment of ethical and human rights obligations.

Citing Articles

Medication for opioid use disorder service delivery in carceral facilities: update and summary report.

Berk J, South A, Martin M, James M, Miller C, Haber L Health Justice. 2025; 13(1):8.

PMID: 39891797 PMC: 11786385. DOI: 10.1186/s40352-025-00317-9.


Medication assisted treatment (MAT) in criminal justice settings as a double-edged sword: balancing novel addiction treatments and voluntary participation.

Hyatt J, Lobmaier P Health Justice. 2020; 8(1):7.

PMID: 32172481 PMC: 7071668. DOI: 10.1186/s40352-020-0106-9.


Probation clients' barriers to access and use of opioid use disorder medications.

Reichert J, Gleicher L Health Justice. 2019; 7(1):10.

PMID: 31139961 PMC: 6717960. DOI: 10.1186/s40352-019-0089-6.


Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder.

Evans E, Zhu Y, Yoo C, Huang D, Hser Y Addiction. 2019; 114(8):1396-1404.

PMID: 30916463 PMC: 6626574. DOI: 10.1111/add.14620.


How Drug Control Policy and Practice Undermine Access to Controlled Medicines.

Burke-Shyne N, Csete J, Wilson D, Fox E, Wolfe D, Rasanathan J Health Hum Rights. 2017; 19(1):237-252.

PMID: 28630556 PMC: 5473053.


References
1.
Tomasino V, SWANSON A, Nolan J, Shuman H . The Key Extended Entry Program (KEEP): a methadone treatment program for opiate-dependent inmates. Mt Sinai J Med. 2001; 68(1):14-20. View

2.
Farrell M, Boys A, Singleton N, Meltzer H, Brugha T, Bebbington P . Predictors of mental health service utilization in the 12 months before imprisonment: analysis of results from a national prisons survey. Aust N Z J Psychiatry. 2006; 40(6-7):548-53. DOI: 10.1080/j.1440-1614.2006.01836.x. View

3.
Choopanya K, Des Jarlais D, Vanichseni S, Kitayaporn D, Mock P, Raktham S . Incarceration and risk for HIV infection among injection drug users in Bangkok. J Acquir Immune Defic Syndr. 2002; 29(1):86-94. DOI: 10.1097/00126334-200201010-00012. View

4.
Cravioto P, Medina-Mora M, De la Rosa B, Galvan F, Tapia-Conyer R . [Patterns of heroin consumption in a jail on the northern Mexican border: barriers to treatment access]. Salud Publica Mex. 2003; 45(3):181-90. View

5.
Volkow N, Li T . The neuroscience of addiction. Nat Neurosci. 2005; 8(11):1429-30. DOI: 10.1038/nn1105-1429. View